Pathos AI AI Access Timeline
Reviewed Strategic Signal records on Pathos AI’s AI access relationships, rights, and disclosed economics.
These selected timelines include reviewed registry records that explicitly name each organization in a participant field. A product, affiliate, or parent name alone does not establish participation. Coverage reflects Strategic Signal’s research sample. Records are ordered by original announcement date. A record may reflect later amendments or evidence updates.
Oct 23, 2026 · Data-rights qualified
Tempus AI → Pathos AI
Up to 500,000 de-identified patient records covering Alzheimer's disease and other specified neurological conditions, targeted for delivery at 100,000 records per year over five years with update availability.
Pathos AI role · AI recipient · Strategic buyer or operator
- Provider / asset owner — Tempus AI
- AI recipient — Pathos AI
- Strategic buyer or operator — Pathos AI
Recorded status · agreement disclosed active term. Last reviewed Oct 27, 2026.
Access · corpus delivery. Training rights · not disclosed.
Disclosed economics · Up to $55 million: $50 million at $100 per delivered record plus $5 million for availability of record updates; realized cash receipts depend on delivery and are not verified. Scope · The filing separately identifies record-license fees and update availability; no standalone value is assigned to the Tempus Agent.
Evidence
Apr 23, 2025 · Data-rights qualified
Tempus AI → Pathos AI
A de-identified multimodal oncology dataset licensed for a foundation-model development program.
Pathos AI role · AI recipient · Strategic buyer or operator
- Provider / asset owner — Tempus AI
- AI recipient — Pathos AI
- Strategic buyer or operator — Pathos AI
Recorded status · agreement disclosed; current payment performance not verified. Last reviewed Sep 16, 2026.
Access · training. Training rights · permitted.
Disclosed economics · $200m data-license fees over three years, including $50m upfront payable. Up to 50% may be settled in Pathos preferred shares. Separate $35m flows run from AstraZeneca to Tempus and Tempus to Pathos. Scope · contractually identified data license fees within broader arrangement
Evidence
- Form 8-K filed April 23, 2025, Item 8.01 · primary